» Articles » PMID: 30652071

Wild-type P53 Regulates OTOP2 Transcription Through DNA Loop Alteration of the Promoter in Colorectal Cancer

Overview
Journal FEBS Open Bio
Specialty Biology
Date 2019 Jan 18
PMID 30652071
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy worldwide and remains a major public health issue. Therefore, further investigation is required to delineate the cellular and molecular mechanisms underlying colorectal tumorigenesis. Using CRC data taken from The Cancer Genome Atlas, we determined that the expression of otopetrin 2 (OTOP2) is highly correlated with malignancy grade and rate of patient survival. Here, we report that OTOP2 is down-regulated in cancerous tissues and that elevated OTOP2 effectively suppresses tumor proliferation . We demonstrate that wild-type p53 (wtp53), but not mutant p53 (mtp53), can regulate the transcription of in CRC cells. Subsequently, we investigate the chromatin architecture of the promoter, whereby we discover alterations in p53-dependent DNA loop organization and CCCTC-binding factor (CTCF) binding between cells with wtp53 and mtp53. In conclusion, our study promotes an in-depth understanding of tumorigenesis, which may also lead to the development of therapeutic applications targeting human malignancy.

Citing Articles

Bestrophin-4 relays HES4 and interacts with TWIST1 to suppress epithelial-to-mesenchymal transition in colorectal cancer cells.

Wang Z, Xia B, Qi S, Zhang X, Zhang X, Li Y Elife. 2024; 12.

PMID: 39699952 PMC: 11658771. DOI: 10.7554/eLife.88879.


COADREADx: A comprehensive algorithmic dissection of colorectal cancer unravels salient biomarkers and actionable insights into its discrete progression.

Palaniappan A, Muthamilselvan S, Sarathi A PeerJ. 2024; 12:e18347.

PMID: 39484215 PMC: 11526798. DOI: 10.7717/peerj.18347.


Structural mechanism of proton conduction in otopetrin proton channel.

Gan N, Zeng W, Han Y, Chen Q, Jiang Y Nat Commun. 2024; 15(1):7250.

PMID: 39179582 PMC: 11343839. DOI: 10.1038/s41467-024-51803-x.


Determination of the Immunomodulatory Role of OTOP2 in Colon Adenocarcinoma.

Lu C, Chen S, Liu S, Liu H, Sun L, Sun Y J Cancer. 2024; 15(15):4838-4852.

PMID: 39132149 PMC: 11310881. DOI: 10.7150/jca.95622.


Pathway2Targets: an open-source pathway-based approach to repurpose therapeutic drugs and prioritize human targets.

Spendlove M, Gibson T, McCain S, Stone B, Gill T, Pickett B PeerJ. 2023; 11:e16088.

PMID: 37790614 PMC: 10544355. DOI: 10.7717/peerj.16088.


References
1.
Li Q, Lei Y, Du W . A Novel Target of p53, TCF21, Can Respond to Hypoxia by MAPK Pathway Inactivation in Uterine Corpus Endometrial Carcinoma. DNA Cell Biol. 2018; 37(5):473-480. DOI: 10.1089/dna.2017.4062. View

2.
Garufi A, Ubertini V, Mancini F, DOrazi V, Baldari S, Moretti F . The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells. J Exp Clin Cancer Res. 2015; 34:87. PMC: 4546314. DOI: 10.1186/s13046-015-0206-x. View

3.
Luo H, Wang F, Zha J, Li H, Yan B, Du Q . CTCF boundary remodels chromatin domain and drives aberrant gene transcription in acute myeloid leukemia. Blood. 2018; 132(8):837-848. PMC: 6107877. DOI: 10.1182/blood-2017-11-814319. View

4.
Hadjipetrou A, Anyfantakis D, Galanakis C, Kastanakis M, Kastanakis S . Colorectal cancer, screening and primary care: A mini literature review. World J Gastroenterol. 2017; 23(33):6049-6058. PMC: 5597496. DOI: 10.3748/wjg.v23.i33.6049. View

5.
Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View